BIOLASE Technology, Inc. Issued New Patents That Extend Core Laser Technology and Capture New Product Offerings

IRVINE, CA--(Marketwire - July 20, 2011) - BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental laser manufacturer and distributor, today announced that the U.S. Patent and Trademark Office has issued BIOLASE three patents focused on core and newly pioneered aspects of its proprietary Er,Cr:YSGG and Er:YAG hard tissue laser technology. With these additions, BIOLASE now has 148 diversified patents issued worldwide and a total of 287 patents and patents pending, providing multiple layers of time-extended protection over a broad range of methods and apparatus.

New patent number 7,970,027, titled "Electromagnetic Energy Distributions for Electromagnetically Induced Mechanical Cutting," continues and expands upon patent number 7,817,687 with broad claims relating to BIOLASE's core technology of using erbium laser energy and fluids such as water as part of a process that results in cutting hard tissue like teeth and bone. The new patent's claims cover current constructions of even the earliest products incorporating BIOLASE's proprietary Waterlase® Er,Cr:YSGG technology, recognized by leading dental professionals as the biologically friendly and essentially painless surgical device for hard and soft tissue, as well as the Er:YAG.

New patent numbers 7,957,440 and 7,970,030, titled "Dual Pulse-Width Medical Laser" and "Dual Pulse-Width Medical Laser with Presets," respectively, expand upon the protection of patent number 7,630,420 adding strength to BIOLASE's newer intellectual property related to altering a laser pulse and associated fluid spray characteristics in order to essentially simultaneously provide dual cutting advantages such as optimizing cutting while controlling bleeding for a wide variety of biological tissues.

Federico Pignatelli, Chairman and CEO, commented, "We view these three new patents as stronger than our earlier work covering erbium laser and water cutting technology, which now extends our intellectual property (IP) coverage well into 2026. While extending exclusivity rights to various aspects utilized within our core Waterlase Er,Cr:YSGG technology, the new patents also augment protection for many newer features and alternatives such as the other wavelengths that could be used in the field."

Chief Technology Officer Dmitri Boutoussov, PhD, said, "These new patents join our many longstanding patents reflecting key features of our laser-induced biological cutting and ablation with water architectures, plus other technological advances in methods and apparatus greatly enhancing safety and efficiency."

About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the World's leading Dental Laser company, is a medical technology company that develops, manufactures and markets dental lasers and also distributes and markets dental imaging equipment, products that are focused on technologies that advance the practice of dentistry and medicine. The Company's laser products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. Its imaging products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on laser and Waterlase dentistry, find BIOLASE at http://www.biolase.com, Twitter at http://twitter.com/GoWaterlase, and YouTube at http://www.youtube.com/user/Rossca08.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.